Effect of Tadalafil on cardiac function and left ventricular dimensions in Duchenne muscular dystrophy: safety and cardiac MRI substudy results from a randomized, placebo-controlled trial
Abstract Background Inhibition of phosphodiesterase 5 (PDE5) was hypothesized to slow disease progression in Duchenne muscular dystrophy (DMD). Tadalafil, a once-daily PDE5 inhibitor, did not slow loss of ambulation in a phase 3 placebo-controlled trial. This report details the cardiac findings from...
Saved in:
| Main Authors: | David Cox, Barry Byrne, David W. Hammers, John Landry, H. Lee Sweeney |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Cardiovascular Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12872-025-04727-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiac MRI in Duchenne and Becker Muscular Dystrophy
by: Manu Santhappan Girija, et al.
Published: (2024-10-01) -
Orthopaedic Management in Duchenne Muscular Dystrophy
by: Uma Balachandran, BA, et al.
Published: (2025-02-01) -
Duchenne muscular dystrophy: an historical treatment review
by: Lineu Cesar Werneck, et al. -
Cardiac Histopathology in Duchenne Muscular Dystrophy Demonstrates Diffuse Fibrofatty Replacement of the Myocardium
by: Andrea Breaux, et al.
Published: (2024-11-01) -
Duchenne muscular dystrophy - disease characterization and emergent genetic therapy - literature review
by: Anna Teresa Michalska, et al.
Published: (2025-07-01)